Hospital-acquired pneumonia in critically III patients: Factors associated with episodes due to imipenem-resistant organisms

Infection

Volumn 33, Issue 3, 2005, Pages 129-135

  Leroy, O ^a   D'Escrivan, T ^b   Devos, P ^c   Dubreuil, L ^b   Kipnis, E ^b   Georges, H ^b  

^a UNIV LILLE   (France)

^b Chatiliez Hospital   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITALIZATION; HUMAN; INFECTIOUS PNEUMONIA; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MICROORGANISM DETECTION; MORBIDITY; MULTIVARIATE ANALYSIS; PREVALENCE; PSEUDOMONAS AERUGINOSA; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE; STENOTROPHOMONAS MALTOPHILIA; THORAX RADIOGRAPHY;

ACINETOBACTER BAUMANNII; AGED; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; IMIPENEM; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; RISK FACTORS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

EID: 21144450539     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-4021-8     Document Type: Article

References (42)

1. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C: Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281-288.
2. Kollef MH, Silver P, Murphy DM, Trovillion E: The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995; 108: 1655-1662.
3. Fagon JY, Chastre J, Vuagnat A, Trouillet JL, Novara A, Gibert C: Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996; 275: 866-869.
4. Papazian L, Bregeon F, Thirion X, Gregoire R, Saux P, Denis JP, Perin G, Charrel J, Dumon JF, Auffray JP, Gouin F: Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996; 154: 91-97.
5. Leroy O, Guilley J, Georges H, Choisy P, Guery B, Alfandari S, Beaucaire G: Effect of hospital-acquired ventilator-associated pneumonia on mortality of severe community-acquired pneumonia. J Crit Care 1999; 14: 12-19.
6. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C: The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999; 159: 1249-1256.
7. Leroy O, Sanders V, Girardie P, Devos P, Yazdanpanah Y, Georges H, Beaucaire G: Mortality due to ventilator-associated pneumonia: impact of medical versus surgical ICU admittance status. J Crit Care 2001; 16: 90-97.
8. Bercault N, Boulain T: Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001; 29: 2303-2309.
9. Torres A, Aznar R, Gatell JM, Jimenez P, Gonzalez J, Ferrer A, Celis R, Rodriguez-Roisin R: Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 523-528.
10. Luna CM, Vujacich P, Niederman MS, Vay C, Cherardi C, Matera J, Jolly EC: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-685.
11. Kollef MH, Ward S: The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113: 412-420.
12. Moine P, Timsit JF, de Lassence A, Troche G, Fosse JP, Alberti C, Cohen Y, OUTCOMEREA study group: Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study. Int Care Med 2002; 28: 154-163.
13. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-268.
14. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J: Variations in etiology of ventilator-associated pneumonia across four treatment sites. Implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160: 608-613.
15. Namias N, Samiian L, Nino D, Shirazi E, O'Neill K, Kett DH, Ginzburg E, McKenney MG, Sleeman D, Cohn SM: Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 2000; 49: 638-645.
16. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J: Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and rends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001; 32 (Suppl. 2): S104-S113.
17. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R: Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl. 2): S146-S155.
18. Jones RN, Biedenbach DJ, Gales AC: Sustained activity and spectrum of selected extended-spectrum beta-lactams against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Chemother 2003; 21: 1-7.
19. Fluit AC, Verhoef J, Schmitz FJ, European SENTRY participants: Antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur J Clin Microbiol Infect Dis 2001; 20: 617-625.
20. American Thoracic Society: Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med 1995; 153: 1711-1725.
21. Kollef MH, Fraser VJB: Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134: 298-314.
22. McCabe WR, Jackson CG: Gram-negative bacteremia: etiology and ecology. Arch Intern Med 1962; 110: 847-855.
23. Le Gall JR, Lemeshow S, Saulnier F: Simplified Acute Physiologic Score. A new simplified acute physiologic score (SAPSII) based on European/North American multicenter study. JAMA 1993; 27: 2957-2963.
24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: Prognosis in acute organ system failure. Ann. Surg 1985; 202: 685-693.
25. Teasdale G, Jennet B: Assessment of coma and impaired consciousness. Lancet 1974; ii: 81-84.
26. Bone RC, Fischer CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA: The methylprednisolone severe sepsis study group. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17: 389-393.
27. Antibiogram Committee of the French Society for Microbiology Official Statement. Pathol Biol 1999; 47: 845-872.
28. SAS Institute Inc.: SAS/STAT guide for personal computers, version 8.2 ed. Cary, North Carolina: SAS Institute, 2001.
29. Paterson DL, Rice LB: Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003; 36: 1006-1012.
30. Kollef MH: Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 2001; 5: 189-195.
31. Kollef MH: Hospital-acquired pneumonia and de-escalation of antimicrobial treatment. Crit Care Med 2001; 29: 1473-1475.
32. Höffken G, Niederman MS: Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122: 2183-2196.
33. Leone M, Bourgoin A, Cambon S, Dubuc M, Albanese J, Martin C: Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003; 31: 462-467.
34. Leroy O, Girardie P, Yazdanpanah Y, Georges H, Alfandari S, Sanders V, Devos P, Beaucaire G: Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens. Eur Respir J 2002; 20: 432-439.
35. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531-539.
36. Kollef MH, Sherman C, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections. Chest 1999; 115: 462-474.
37. Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, Fabian TC: Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002; 35: 228-235.
38. Rello J, Ausina V, Ricart M, Puzo C, Quintana E, Net A, Prats G: Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med 1994; 20: 193-198.
39. Rello J, Torres A, Ricart M, Valles J, Gonzalez J, Artigas A, Rodriguez-Roisin R: Ventilator-associated pneumonia by Staphylococcus aureus. Am J Respir Crit Care Med 1994; 150: 1545-1549.
40. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y: Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 2002; 34: 1558-1563.
41. Paterson DL: Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis 2002; 34: 1564-1567.
42. European Task Force on Ventilator-Associated Pneumonia: Ventilator-associated pneumonia. Eur Respir J 2001; 17: 1034-1045.